These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 2981332)

  • 1. Evidence for at least two dominant neutralization antigens on human rhinovirus 14.
    Sherry B; Rueckert R
    J Virol; 1985 Jan; 53(1):137-43. PubMed ID: 2981332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14.
    Sherry B; Mosser AG; Colonno RJ; Rueckert RR
    J Virol; 1986 Jan; 57(1):246-57. PubMed ID: 2416951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization epitopes of human rhinovirus type 2.
    Appleyard G; Russell SM; Clarke BE; Speller SA; Trowbridge M; Vadolas J
    J Gen Virol; 1990 Jun; 71 ( Pt 6)():1275-82. PubMed ID: 1693662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
    Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
    J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the location of antigenic sites of swine vesicular disease virus with neutralization-resistant mutants.
    Kanno T; Inoue T; Wang Y; Sarai A; Yamaguchi S
    J Gen Virol; 1995 Dec; 76 ( Pt 12)():3099-106. PubMed ID: 8847515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-AgIB of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152.
    Wiegers K; Uhlig H; Dernick R
    Virology; 1989 Jun; 170(2):583-6. PubMed ID: 2471354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of monoclonal antibodies raised against a synthetic peptide capable of inducing a neutralizing response to human rhinovirus type 2.
    Barnett PV; Rowlands DJ; Parry NR
    J Gen Virol; 1993 Jul; 74 ( Pt 7)():1295-302. PubMed ID: 8393073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies.
    Ping LH; Lemon SM
    J Virol; 1992 Apr; 66(4):2208-16. PubMed ID: 1312628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus.
    Ping LH; Jansen RW; Stapleton JT; Cohen JI; Lemon SM
    Proc Natl Acad Sci U S A; 1988 Nov; 85(21):8281-5. PubMed ID: 2460866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cross-reactive and serotype 2-specific neutralization epitopes on VP3 of human rotavirus.
    Taniguchi K; Maloy WL; Nishikawa K; Green KY; Hoshino Y; Urasawa S; Kapikian AZ; Chanock RM; Gorziglia M
    J Virol; 1988 Jul; 62(7):2421-6. PubMed ID: 2453680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites.
    Xie QC; McCahon D; Crowther JR; Belsham GJ; McCullough KC
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1637-47. PubMed ID: 2438378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
    Blondel B; Crainic R; Fichot O; Dufraisse G; Candrea A; Diamond D; Girard M; Horaud F
    J Virol; 1986 Jan; 57(1):81-90. PubMed ID: 2416957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2.
    Francis MJ; Hastings GZ; Sangar DV; Clark RP; Syred A; Clarke BE; Rowlands DJ; Brown F
    J Gen Virol; 1987 Oct; 68 ( Pt 10)():2687-91. PubMed ID: 2822846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies to human rhinovirus produced in laboratory animals and humans that recognize a linear sequence from VP2.
    Hastings GZ; Speller SA; Francis MJ
    J Gen Virol; 1990 Dec; 71 ( Pt 12)():3055-9. PubMed ID: 1703215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nature and spatial distribution of amino acid substitutions conferring resistance to neutralizing monoclonal antibodies in human rhinovirus type 2.
    Speller SA; Sangar DV; Clarke BE; Rowlands DJ
    J Gen Virol; 1993 Feb; 74 ( Pt 2)():193-200. PubMed ID: 8381460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of a poliovirus/rhinovirus antigenic hybrid.
    Altmeyer R; Murdin AD; Harber JJ; Wimmer E
    Virology; 1991 Oct; 184(2):636-44. PubMed ID: 1653493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and antigenic variation of the structural protein VP3 in serotype 1 poliovirus isolated from vaccinees.
    Cash P
    Can J Microbiol; 1988 Jun; 34(6):802-6. PubMed ID: 2849500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of neutralizing monoclonal antibodies to empty capsids of poliovirus can be blocked by monospecific antisera to structural polypeptides VP1 and VP2.
    Uhlig H; Haardt F; Dernick R
    Arch Virol; 1985; 83(3-4):295-303. PubMed ID: 2578787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of rhinovirus intertypes related to either rhinoviruses 12 and 78 or 36 and 58.
    Halfpap LM; Cooney MK
    Infect Immun; 1983 Apr; 40(1):213-8. PubMed ID: 6299958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.
    Zhang A; Geisler SC; Smith AD; Resnick DA; Li ML; Wang CY; Looney DJ; Wong-Staal F; Arnold E; Arnold GF
    Biol Chem; 1999 Mar; 380(3):365-74. PubMed ID: 10223339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.